RE:RE:RE:Kane Biotech Announces New Collaboration Agreements also it was plainly in this statment from 2nd Q 2021 MD&A released Aug 26th 2021 which is the same statement made on the year end 2020 MD&A released Mar 25th 2021....frankly surprised that you MirrorWorldMan didn't know or find what is so easily to find in their all the MD&A's of at least the past year and a half as well as presentations from 2019.
'....Kane is currently investigating the opportunity of using DispersinB® Gel for Prosthetic Joint Infection (PJI). PJI’s have been identified as one of the most serious complications of joint replacement surgery with bacterial biofilm on the prostheses being identified as one of the key problems in treatment. PJI’s are one of the most serious complications of joint replacement surgery. Conservative estimates are that approximately 1– 2% of all prostheses will become infected over the life of the implant. The financial burden of treating these infections is staggering. It was estimated that it would cost the US healthcare system $1.62 billion in 2020. In addition, patients have significant morbidity and mortality as a direct result of our current medical and surgical management to treat these infections. PJIs are hard to treat because of bacterial biofilms on the prostheses. Unfortunately, conventional antibiotics have limited ability to resolve biofilm infections. This is in part due to the almost dormant metabolic activity of bacteria in biofilms and the architecture of biofilms. The concentrations of conventional antibiotics needed to have activity to bacteria in biofilms can be up to 1000 times higher than the same bacteria in a planktonic state. Therefore, new antimicrobial therapies are needed to treat PJI’s that focus on disrupting biofilms. In the Human Health OTC Division, a technical brief has been completed and is under review for the development of a DispersinB® acne wash upon securing a strategic partner to assist in final product formulation, conducting clinical trials and developing the regulatory strategy.'